Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.
about
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Genetic Characterization of a Novel HIV-1 Circulating Recombinant Form (CRF74_01B) Identified among Intravenous Drug Users in Malaysia: Recombination History and Phylogenetic Linkage with Previously Defined Recombinant LineagesOverview of HIV molecular epidemiology among people who inject drugs in Europe and Asia.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesInitiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAn HIV Vaccine for South-East Asia-Opportunities and Challenges.Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env SequencesAn Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.Impact of early cART in the gut during acute HIV infectionEvaluation of Hologic Aptima HIV-1 Quant Dx Assay on the Panther System on HIV Subtypes.Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.Fourth generation assays for HIV testing.Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
P2860
Q27687375-EF60D3AD-61EC-4B9B-B305-1E5DDFC78855Q28546683-595E76A5-9FC2-4925-A914-9797B28EF1C2Q30249677-D3BDB2B0-AF94-4CC5-852E-CBB200798D4AQ33804531-9FAA9D83-DE9B-4DB9-94D6-D87D79086A9BQ34057711-70B175C7-83FD-4E29-BB66-2384DC3979B0Q34682171-36840B70-E296-4B42-A6C8-3E67204084EDQ35826681-55071541-9CB2-42CF-8950-C6C8FD88C710Q35915764-ABCB9795-44E1-481C-81A5-D20544CEAC5EQ36218713-3D45EAA5-E4B4-4F9C-957E-49403DB59704Q37109215-CCB84E86-E30A-4E7A-80E0-F451B6BEC732Q37280582-1E5A96DC-D4AA-44A1-B300-B9B27783E738Q37729781-D30A4234-529C-46E0-B609-02124DC17F10Q38243948-23D80FAE-2AA2-48BD-B8B3-DCA41B05D31EQ40707370-BC885141-92B8-4143-A7DB-B1A064680CEBQ52660832-397D3DE4-940C-48C8-83E9-873275560A98Q55447637-C6FF7BF3-07CB-41F1-A714-BC3DBA7B7D10
P2860
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Molecular evolution of the HIV ...... of the vaccine efficacy trial.
@en
type
label
Molecular evolution of the HIV ...... of the vaccine efficacy trial.
@en
prefLabel
Molecular evolution of the HIV ...... of the vaccine efficacy trial.
@en
P2093
P2860
P50
P356
P1433
P1476
Molecular evolution of the HIV ...... of the vaccine efficacy trial.
@en
P2093
Chawetsan Namwat
Chirapa Eamsila
Chirasak Khamboonruang
Gustavo H Kijak
Mark S De Souza
Meera Bose
Michael Benenson
Nakorn Premsri
Patricia Morgan
Prasert Thongcharoen
P2860
P304
P356
10.1128/JVI.03070-12
P407
P50
P577
2013-04-10T00:00:00Z